Skip to main content
TipRanks
Go Ultimate75% OFF

Vanda (VNDA) AI Stock Analysis

699 Followers
VNDA

Vanda

(NASDAQ:VNDA)

Select Model
Rating:49Neutral
Price Target:$3.50â–¼(-8.14% Downside)
Action:reiterated
Date:10/29/26

VNDA scores below average primarily due to deteriorating profitability and accelerating cash burn, which outweigh a balance-sheet leverage cushion. Technicals also detract as the stock trades below major moving averages with bearish momentum, though oversold indicators hint pressure may be extended. The latest earnings call provides some support via stronger revenue trends, upcoming launches, and expense reductions, but near-term funding/runway risk remains elevated given the cash decline and higher expected cash burn.

Positive Factors
Fanapt commercial momentumFanapt is showing durable commercial traction following its bipolar I expansion, with higher sales, prescriptions, and new-to-brand demand. Continued volume growth and broader prescriber reach can support recurring revenue and help establish a stronger base before future exclusivity pressure emerges.
Negative Factors
Severe profitability deteriorationThe move from near-breakeven results in 2024 to heavy losses in 2025 and the TTM period indicates that revenue is not currently supporting the operating structure. Persistent negative margins can weaken internal funding capacity and make future growth increasingly dependent on cash reserves or external financing.

Vanda (VNDA) vs. SPDR S&P 500 ETF (SPY)

-50%-25%0%25%50%75%100%VNDA-21.28%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$230.39M
Dividend Yield
―
Average Volume (3M)
1.05M
Price to Earnings (P/E)
-0.8
Beta (1Y)
0.58
Revenue Growth
8.11%
EPS Growth
-222.50%
Country
US
Employees
533
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Vanda Business Overview & Revenue Model

Company Description

Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-2...

How the Company Makes Money

Vanda makes money primarily by selling prescription pharmaceuticals. Its revenue is generated from (1) product sales of its marketed drugs—HETLIOZ, Fanapt, and PONVORY—through distribution to wholesalers/specialty pharmacies and ultimately to healthc...

Vanda Earnings Call Summary

Earnings Call Date:Oct 28, 2026(Q3-2026)|% Change Since:-4.75%|Next Earnings Date:Feb 10, 2027
Earnings Call SentimentPositive

The call was broadly positive, supported by 24% third-quarter revenue growth, strong Fanapt prescription trends, positive NEREUS and HETLIOZ clinical results, the expected BYSANTI launch, the Quimilza regulatory milestone, and declining quarterly operating expenses. These positives were partly offset by a larger year-to-date net loss, a substantial cash balance decline, expected higher 2026 cash burn, continued generic pressure on HETLIOZ, constrained early NEREUS revenue, and ongoing regulatory proceedings.

Positive Updates

Third-Quarter Revenue Growth
Total revenues were $69.8 million in the third quarter of 2026, increasing 24% compared to $56.3 million in the third quarter of 2025 and 38% compared to $50.5 million in the second quarter of 2026. The increases were primarily due to higher HETLIOZ revenue from the timing of specialty pharmacy purchases and customer shipments, along with Fanapt growth from the bipolar I commercial launch.

Negative Updates

Higher Year-to-Date Net Loss
For the first nine months of 2026, Vanda recorded a net loss of $133.6 million compared with a net loss of $79.3 million in the same period of 2025. The 2026 loss included $0.4 million of income tax expense, compared with a $21.4 million income tax benefit in the comparable 2025 period.

Company Guidance

Vanda updated its full year 2026 total revenue guidance, expecting total revenues from Fanapt, BYSANTI, HETLIOZ, PONVORY, and NEREUS of greater than $240 million; NEREUS revenue is likely to be less than $10 million for the full year of 2026, while NEREUS total prescriptions and unique prescribers in Q3 2026 increased by over 100% versus Q2 2026. Vanda is not providing 2026 cash guidance at this time, but it is likely that Vanda's 2026 cash burn will be greater than the cash burn in 2025. Operating expenses decreased by 18% to $93.3 million from $114.3 million in Q2 of 2026 and are expected to decrease further in future quarterly periods. BYSANTI is expected to launch in the fourth quarter of 2026, Quimilza could be ready with commercial product a few months after December, with the goal of being on the market in the first half of 2027, and the BYSANTI MDD study is expected to complete in the first half of 2027.

Vanda Financial Statement Overview

Summary

Despite modest TTM revenue growth (+6.3%) and a low-leverage balance sheet (TTM debt-to-equity ~0.09), fundamentals are pressured by sharply worsened profitability (very large operating losses; net margin ~-120%) and decisively negative cash generation (deeply negative TTM operating cash flow and free cash flow with further contraction).

Income Statement

28Negative

Balance Sheet

74Positive

Cash Flow

24Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue229.28M216.10M198.77M192.64M254.38M268.68M
Gross Profit212.59M203.06M187.46M177.84M230.10M243.05M
EBITDA-162.09M-126.73M-14.79M9.35M14.03M45.20M
Net Income-274.83M-220.47M-18.90M2.51M6.28M33.15M
Balance Sheet
Total Assets382.33M488.95M656.20M648.44M634.25M593.79M
Cash, Cash Equivalents and Short-Term Investments140.49M263.85M374.64M388.26M466.86M432.81M
Total Debt21.97M12.62M12.36M9.40M11.14M12.37M
Total Liabilities182.47M161.76M117.66M103.53M107.05M88.86M
Stockholders Equity199.86M327.19M538.55M544.91M527.20M504.93M
Cash Flow
Free Cash Flow-190.40M-110.44M-16.25M12.42M31.30M63.66M
Operating Cash Flow-189.36M-109.44M-15.76M12.80M31.98M64.21M
Investing Cash Flow154.35M94.86M-17.43M-12.06M49.92M-76.70M
Financing Cash Flow-3.92M-2.91M-155.00K0734.00K3.55M

Vanda Technical Analysis

Technical Analysis SentimentNegative
Last Price3.81

Price Trends

50DMA4.43Negative
100DMA4.96Negative
200DMA5.98Negative

Market Momentum

MACD-0.14Negative
RSI40.60Neutral
STOCH48.41Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VNDA, the sentiment is Negative. The current price of 3.81 is below the 20-day moving average (MA) of 3.93, below the 50-day MA of 4.43, and below the 200-day MA of 5.98, indicating a bearish trend. The MACD of -0.14 indicates Negative momentum. The RSI at 40.60 is Neutral, neither overbought nor oversold. The STOCH value of 48.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VNDA.

Vanda Risk Analysis

Vanda disclosed 60 risk factors in its most recent earnings report. Vanda reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

3 New Risks
1.Our business may be materially adversely affected by the imposition of duties and tariffs and other trade barriers and retaliatory countermeasures implemented by the U.S. and other governments.Q2, 2026
2.Artificial intelligence presents risks and challenges that can impact our business including by posing security risks to our confidential information, proprietary information, and personal data.Q4, 2025
3.Disruptions at the FDA and other government agencies caused by, among other things, government shutdowns, could hinder their ability to hire, retain or deploy key leadership and other personnel, conduct inspections of manufacturing facilities or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.Q4, 2025

Vanda Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

VNDA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
VNDAVNDA49Neutral$230.39M-0.83-106.94%―8.11%-222.50%
NRXPNRXP47Neutral$108.60M-4.53247.77%―1681.40%77.82%
AVXLAVXL46Neutral$68.60M-4.97-11.43%――73.28%
NERVNERV41Neutral$107.64M-0.08167.68%――-1306.84%
NMRANMRA40Underperform$63.12M-0.29-320.56%――27.16%
MPLTMPLT39Underperform$365.13M-1.20-61.01%―――

* Healthcare Sector Average

Performance Comparison

0%100%VNDANERVAVXLNRXPNMRAMPLTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
VNDA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
VNDAVanda Pharmaceuticals3.81-1.33-25.88%
NERVMinerva Neurosciences2.16-2.14-49.77%
AVXLAnavex Life Sciences0.74-2.86-79.44%
NRXPNrx Pharmaceuticals, Inc.2.450.3215.02%
NMRANeumora Therapeutics, Inc.0.33-2.21-86.85%
MPLTMapLight Therapeutics, Inc.6.57-8.03-55.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 29, 2026